Insight: Stifel Downgrades ALX Oncology’s Evorpacept to Hold Insight: Stifel Downgrades ALX Oncology’s Evorpacept to Hold
The Downgrade Stifel’s recent decision to downgrade ALX Oncology (NASDAQ:ALXO) to hold has reverberated across the investment landscape. It attributed this move to its perception that the company’s CD47 blocker drug evorpacept is now fully valued for the de-risked HER2+ gastric cancer opportunity. Optimism Amid …